Clinical Trial Update: The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP) [Phase 2]

View source ↗

Summary

The HIV Prevention Trials Network completed the Phase 2 ADAPT study evaluating emtricitabine/tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: HIV Prevention Trials Network | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2017-05-12